TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9543133
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day, n = 16)
Study: 9543133
Drug: Toremifene (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (40 mg/day, n = 14)
Study: 2726331
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A (10 micrograms of hepatitis B vaccine at 0, 1, 2, and 11 months)
Study: 2726331
Drug: Schedule B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B (10 micrograms of hepatitis B vaccine at 3, 4, 5, and 11 months)
Study: 14608552
Drug: Routine nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine nursing care treatment (control group)
Study: 1578079
Drug: UV‐A condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV‐A condition (light therapy with UV-A wavelengths)
Study: 1578079
Drug: UV-blocked condition
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV-blocked condition (light therapy without UV-A wavelengths)
Study: 3933645
Drug: Methylprednisolone pulses
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulses followed by low dose oral prednisone for six months
Study: 3933645
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral prednisone for four weeks followed by low dose oral prednisone for five months
Study: 18001250
Drug: Bromfenac ophthalmic
Normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac ophthalmic solution 0.09%
Study: 27531286
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (dexamethasone 0.1% and tobramycin 0.3%) alone
Study: 22335395
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention consisting of self‐monitored blood pressure, medicine review, a Digital Versatile Disc, and motivational interviewing telephone calls over 3 months.
Study: 20003697
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (MXF) 400 mg daily for the first 2 months
Study: 20003697
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen plus daily 400 mg MXF
Study: 7477192
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (t‐PA)
Study: 30607782
Drug: Omega-3 long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 long chain polyunsaturated fatty acids (722 mg docosahexaenoic acid)
Study: 30607782
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2000 IU daily)
Study: 25443863
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) - single session
Study: 21150467
Drug: Irinotecan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (50 mg/m on days 1, 8, and 15) plus paclitaxel (180 mg/m on day 1) every 4 weeks (IP group)
Study: 21150467
Drug: Irinotecan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (100 mg/m on days 1 and 8) plus gemcitabine (1000 mg/m on days 1 and 8) every 3 weeks (IG group)
Study: 2595103
Drug: NaHCO3 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (300 mg/kg body weight)
Study: 2595103
Drug: CaCO3 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCO3 (300 mg/kg body weight)
Study: 4933388
Drug: DEAE Sephadex
Normalized name: DEAE-rebeccamycin
DrugBank: Becatecarin (DB06362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEAE Sephadex (12‐15 g/day)
Study: 9866536
Drug: Blood sampling
Normalized name: TERUFLEX Blood with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative for Collection of 450mL of Blood KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood sampling from peripheral intravenous infusion lines
Study: 7715904
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron i.v. + placebo p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Study: 7715904
Drug: Placebo i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v. + 8 mg ondansetron p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Study: 7715904
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg granisetron i.v. + placebo p.o. before chemotherapy + placebo p.o. b.d. until day 5
Study: 2462067
Drug: Luteinizing hormone‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone‐releasing hormone agonist buserelin
Study: 880971
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg b.i.d. for 3 weeks and 200 mg b.i.d. for 3 weeks)
Study: 30300021
Drug: Combined laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined laser with topical photo‐enhancer gel
Study: 30300021
Drug: Solo laser
Normalized name: Fallback Solo
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solo laser treatment
Study: 29029097
Drug: Control (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (lower doses)
Study: 25892658
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (.08 mg/kg)
Study: 23356494
Drug: Intravenous iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iloprost after liver transplantation
Study: 21904779
Drug: Pentazocine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (0.3 mg/kg)
Study: 18673303
Drug: Aerobic Interval
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic Interval Training (AIT) - 4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
Study: 18673303
Drug: Multidisciplinary Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary Treatment Group (MTG) - exercise, dietary and psychological advice, twice a month for 12 months
Study: 18673303
Drug: Multidisciplinary Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary Treatment Group (MTG)
Study: 15223085
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 100 mg QD (increased to 200 mg QD after 1 week, with further increases allowed up to 400 mg QD)
Study: 30519976
Drug: General practitioner‐led
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner‐led interprofessional medication assessment
Study: 28349727
Drug: β‐alanine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐alanine group (6.4 g day‐1 of β‐alanine)
Study: 28349727
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (6.4 g day‐1 of dextrose)
Study: 23065656
Drug: Enzastaurin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin (500 mg daily for 6 months)
Study: 17153886
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with standardized P sylvestris pollen extract
Study: 14969156
Drug: Nitroglycerin 15
Normalized name: NITROGLYCERIN 15MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin 15 mg in slow-release form (N-15)
Study: 10928427
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone gel, 90 mg
Study: 10711552
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) progesterone, 50 mg
Study: 23294143
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges containing L. reuteri (ATCC55730 and ATCC PTA5289) taken twice a day
Study: 23294143
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges taken twice a day
Study: 11240881
Drug: Ondansetron 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.04 mg.kg‐1 (1 mg.m‐2)
Study: 11240881
Drug: Ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.1 mg.kg‐1 (2.5 mg.m‐2)
Study: 11240881
Drug: Ondansetron 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.2 mg.kg‐1 (5 mg.m‐2)
Study: 11240881
Drug: Overall Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Overall Ondansetron (all doses)
Study: 3555055
Drug: Single-dose ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ciprofloxacin (500 mg)
Study: 3555055
Drug: Three-day ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-day ciprofloxacin (500 mg twice daily)
Study: 3555055
Drug: Three-day trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day trimethoprim-sulfamethoxazole (160 mg and 800 mg, respectively, twice daily)
Study: 24991787
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of statins
Study: 23690531
Drug: Sulfonylureas, Dipeptidyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Insulin (added to metformin 1,000-2,000 mg/day)
Study: 18836692
Drug: Calcium ascorbate
Normalized name: Calcium Ascorbate
DrugBank: Calcium ascorbate (DB14483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium ascorbate with vitamin C metabolites (two formulations)
Study: 16415712
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (CMI) 150 mg on day 1 and 200 mg on day 2, followed by oral CMI starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Study: 16415712
Drug: Oral clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clomipramine (CMI) starting at 200 mg/d, increased by 25 mg every 4 days to 250 mg/d for 12 weeks.
Study: 3161529
Drug: Midazolam; repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam; repeated doses
Study: 3161529
Drug: Diazepam; similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam; similar doses given with the same frequency
Study: 28474984
Drug: CO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO inhalation (carboxyhemoglobin 22%)
Study: 21262673
Drug: Non-adjuvanted inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted inactivated fungal vaccine
Study: 18853114
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional treatment)
Study: 12737092
Drug: Neurofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback treatment (3-month electroencephalographic feedback program providing reinforcement contingent on the production of cortical sensorimotor rhythm (12-15 Hz) and beta activity (15-18 Hz))
Study: 17714375
Drug: Methylphenidate (stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (stimulant medication)
Study: 10471981
Drug: Tegaserod (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (12 mg oral dose) administered 30 minutes prior to meal
Study: 10471981
Drug: Tegaserod (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (12 mg oral dose) administered 15 minutes prior to meal
Study: 10471981
Drug: Tegaserod (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (12 mg oral dose) administered 1 minute before meal
Study: 10471981
Drug: Tegaserod (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (12 mg oral dose) administered 2.5 hours after meal
Study: 10471981
Drug: Tegaserod (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (12 mg oral dose) administered with a continued 4-hour postdose fast
Study: 1332526
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment (NT) condition
Study: 31764900
Drug: Natural food-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural food-based fiber solution
Study: 22370992
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of arachidonic acid (ARA) added to docosahexaenoic acid (DHA) (n = 7)
Study: 20200197
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon beta-1a
Study: 15644650
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 6 mL/kg predicted body weight
Study: 15644650
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 12 mL/kg predicted body weight
Study: 11824860
Drug: Isotonic volume
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic volume contraction (induced by furosemide infusion and replaced by 5% isotonic glucose infusion)
Study: 1588979
Drug: Inhaled methoxamine
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled methoxamine (10 mg)
Study: 1963135
Drug: Isotretinoin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (10 mg)
Study: 6291889
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg IV bolus)
Study: 6291889
Drug: Cimetidine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (0.12 mg/ml in vitro)
Study: 6291889
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg over 12 hours)
Study: 6291889
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg IV bolus)
Study: 6291889
Drug: Ranitidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (100 mg IV bolus)
Study: 30019768
Drug: Active learning
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active learning education program (weekly 90‐minute sessions for 24 weeks)
Study: 22289659
Drug: Oral PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PTH134 1 mg with 200 mg 5-CNAC
Study: 22289659
Drug: Oral PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PTH134 2.5 mg with 200 mg 5-CNAC
Study: 22289659
Drug: Oral PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PTH134 5 mg with 200 mg 5-CNAC
Study: 22289659
Drug: Oral PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PTH134 10 mg with 200 mg 5-CNAC
Study: 22289659
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 μg sc
Study: 22289659
Drug: Oral PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PTH134 2.5 mg with 100 mg 5-CNAC
Study: 22289659
Drug: Oral PTH134
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PTH134 5 mg with 100 mg 5-CNAC
Study: 20584172
Drug: sFas levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sFas levels in overweight/obese men (2.42 ng mL(‐1))
Study: 20584172
Drug: sFas levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sFas levels in men with hyperlipidaemia (2.34 ng mL(‐1))
Study: 681526
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment strategies
Study: 25996534
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid application after PELD
Study: 25996534
Drug: Saline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline treatment after PELD
Study: 16426098
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to first treatment
Study: 16426098
Drug: Recommendations for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommendations for treatment outcome data acquisition
Study: 15232328
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 60 mg/d)
Study: 15232328
Drug: Testosterone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (up to 400 mg IM testosterone cypionate biweekly)
Study: 9205633
Drug: etidronate 400
Normalized name: etidronate 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: etidronate 400 mg/day
Study: 8094485
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of 0.3‐0.5 ml sterile water
Study: 2959717
Drug: rt-PA (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (0.75 mg/kg)
Study: 2959717
Drug: rt-PA (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (40 or 80 mg)
Study: 2959717
Drug: single chain
Normalized name: Single chain urokinase-like plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: single chain rt-PA (100 mg total)
Study: 29792839
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (ibuprofen 800 mg orally, lidocaine paracervical block, anticipatory guidance)
Study: 25894960
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate treatment (group 1)
Study: 16083195
Drug: Thai-made levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thai-made levonorgestrel pill (0.75 mg)
Study: 16083195
Drug: Hungarian levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hungarian levonorgestrel pill (0.75 mg)
Study: 9401829
Drug: Lubeluzole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 2.5 mg
Study: 9401829
Drug: Lubeluzole 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 5 mg
Study: 9401829
Drug: Lubeluzole 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 10 mg
Study: 9401829
Drug: Lubeluzole 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 15 mg
Study: 9401829
Drug: Lubeluzole 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 20 mg
Study: 9401829
Drug: Lubeluzole 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 25 mg
Study: 8099593
Drug: Cetirizine, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 15 mg twice daily
Study: 3543236
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (high-dose methotrexate, Adriamycin, BCD)
Study: 2840035
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant chemotherapy (control group)
Study: 22883272
Drug: Puerarin Injection
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Puerarin (DB12290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin Injection
Study: 22883272
Drug: Danshen Injection
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danshen Injection
Study: 18657196
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin mix 50
Study: 9862296
Drug: Continuous ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ultrasound therapy at 1.5W/cm2 (group A)
Study: 9862296
Drug: Continuous ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ultrasound therapy at 0.8W/cm2 (group B)
Study: 9862296
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound therapy at 0.0W/cm2 (group C)
Study: 31006996
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CCT) group
Study: 29113968
Drug: norfloxacin (antibiotic)
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norfloxacin (antibiotic)
Study: 26116627
Drug: Spironolactone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5 mg titrated to 25 mg)
Study: 21457929
Drug: Standard-fluence photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-fluence photodynamic therapy (PDT) at 50 J/cm²
Study: 21457929
Drug: Low-fluence photodynamic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluence photodynamic therapy (PDT) at 25 J/cm²
Study: 19344725
Drug: Single intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intranasal dose of oxytocin
Study: 17893153
Drug: Altastaph (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altastaph (200 mg/kg in two infusions 24 hours apart)
Study: 15761542
Drug: Prednisolone (PD)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PD) 2.4-3.5 mg/m2 BSA
Study: 15761542
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 10-15 mg/m2 BSA
Study: 10803800
Drug: tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone 200 mg three times daily
Study: 2457422
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and methotrexate, alternating after four cycles with cyclophosphamide, lomustine, vincristine, and methotrexate + irradiation at 40 Gy
Study: 2457422
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and methotrexate, alternating after four cycles with cyclophosphamide, lomustine, vincristine, and methotrexate
Study: 25854013
Drug: Acupuncture-moxibustion +
Normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-moxibustion + Chinese medicine (group B)
Study: 25854013
Drug: Clomiphene +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene + acupuncture-moxibustion + Chinese medicine (group C)